PT - JOURNAL ARTICLE AU - Alexey Youssef AU - Samaneh Kouchaki AU - Farah Shamout AU - Jacob Armstrong AU - Rasheed El-Bouri AU - Thomas Taylor AU - Drew Birrenkott AU - Baptiste Vasey AU - Andrew Soltan AU - Tingting Zhu AU - David A Clifton AU - David W Eyre TI - Development and Validation of Early Warning Score Systems for COVID-19 Patients AID - 10.1101/2020.11.04.20225904 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.04.20225904 4099 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225904.short 4100 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225904.full AB - COVID-19 is a major, urgent, and ongoing threat to global health. Globally more than 24 million have been infected and the disease has claimed more than a million lives as of October 2020. Predicting which patients will need respiratory support is important to guiding individual patient treatment and also to ensuring sufficient resources are available. We evaluated the ability of six common Early Warning Scores (EWS) to identify respiratory deterioration defined as the need for advanced respiratory support (high-flow nasal oxygen, continuous positive airways pressure, non-invasive ventilation, intubation) within a prediction window of 24 hours. We show these scores perform sub-optimally at this specific task. Therefore, we develop an alternative Early Warning Score based on a Gradient Boosting Trees (GBT) algorithm that is able to predict deterioration within the next 24 hours with high AUROC 94% and an accuracy, sensitivity and specificity of 70%, 96%, 70%, respectively. Our GBT model outperformed the best EWS (LDTEWS:NEWS), increasing the AUROC by 14%. Our GBT model makes the prediction based on the current and baseline measures of routinely available vital signs and blood tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified data from patients were obtained from the Infections in Oxfordshire Research Database (IORD) which has Research Ethics Committee, Health Research Authority and Confidentiality Advisory Group approvals (19/SC/0403, ECC5-017(A)/2009).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to data can be sought through applying to access our dataset via the formal application process.